Clinical spectrum & pathogenesis of Clostridium difficile associated diseases

Indian Journal of Medical Research

Volumn 131, Issue 4, 2010, Pages 487-499

  Vaishnavi, Chetana ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Clinical spectrum; Clostridium difficile; Diagnosis; Pathogenesis; Predisposing factors; Treatment

Indexed keywords

AMINO ACID; AMPICILLIN; ANTIBIOTIC AGENT; BACITRACIN; BACTERIAL VACCINE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID VACCINE; COLESTYRAMINE; CYCLOSERINE; FUSIDIC ACID; GENTAMICIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN; METRONIDAZOLE; NALIDIXIC ACID; NITAZOXANIDE; PENICILLIN G; PROBIOTIC AGENT; RAMOPLANIN; RIFAXIMIN; SULFAMETHOXAZOLE; TEICOPLANIN; TETRACYCLINE; TOLEVAMER; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRITIS; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG CHOICE; ENZYME LINKED IMMUNOSORBENT ASSAY; HOSPITAL PATIENT; HUMAN; IMMUNOELECTROPHORESIS; INTESTINE FLORA; LATEX AGGLUTINATION TEST; MORTALITY; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; REVIEW; SEQUENCE HOMOLOGY;

CARRIER STATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS;

EID: 77951054926     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Hall IC, O'Toole E. Intestinal flora in newborn infants with 1. description of a new pathogenic anaerobe. Am J Dis Child 1935; 49: 390-402.
2. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269: 71-5.
3. George RH, Symonds JM, Dimock F, Brown JD, Arabi Y, Shinnagawa, N et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. BMJ 1978; 1: 695.
4. Larson HE, Price AB, Honour P, Borriello, SP. Clostridium difficile and the etiology of pseudomembranous colitis. Lancet 1978; 1: 1063-6.
5. Falson E, Kaijder B, Nehls L, Nygreu B, Svedham A. Clostridium difficile in relation to enteric bacterial pathogens. J Clin Microbiol 1980; 12: 297-300.
6. Johnson S, Gerding DN. Clostridium difficile. In: May Hall GC, editor. Hospital epidemiology and infection control, 3rd ed. Philadelphia: Lippincott Williams &Wilkins; 2004. p. 623-32.
7. Crogan NL, Evans BC. Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs 2007, 28: 161-4.
8. Pepin J, Saheb N, Coulombe M, Alary M, Corriveau M, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhoea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 254-60.
9. McDonald LC, Killgore GE, Thompson A, Owens RC, Khazakova Jr, Sambol SV, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
10. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North-America and Europe. L ancet 2005; 366: 1079-84.
11. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile associated disease in North America and Europe. Clin Microbiol Infect 2006; 12: 2-18.
12. Cloud J, Kelly CP. Update on Clostridium difficile associated disease. Curr Opin Gastroenterol 2007; 23: 4-9.
13. Riley TV. Epidemic Clostridium difficile. Med J Australia 2006; 185: 133-4.
14. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. Can Med Assoc J 2008; 179: 767-72.
15. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-93.
16. Johnson S, Kent SA, O'Leary KJ, Merrigan MM, Sambol SP, Peterson LR, et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001; 135: 434-8.
17. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding, DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351: 633-6.
18. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45: 992-8.
19. Farrell RJ, LaMont JT. Pathogenesis and clinical manifestations of Clostridium difficile diarrhea and colitis. Curr Top Microbiol Immunol 2000; 250: 109-25.
20. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 1997; 4: 719-22.
21. Vaishnavi C, Bhasin D, Kochhar R, Singh K. Clostridium difficile toxin and faecal lactoferrin assays in adult patients. Microbes Infect 2000; 2: 1827-30.
22. Finney JM. Gastroenterostomy for cicatrizing ulcer of the pylorus. Bull John Hopkins Hosp 1893; 4: 53-5.
23. Gebhard RL, Gerding DN, Olson MM, Peterson LR, McClain CJ, Ansel HJ, et al. Clinical and endoscopic findings in patients early in the course of Clostridium difficile-associated pseudomembranous colitis. Am J Med 1985; 78: 45-8.
24. Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 1982; 77: 220-1.
25. Zuckerman E, Kanel G, Ha C, Kahn J, Gottesman BS, Korula J. Low albumin gradient ascites complicating severe pseudomembranous colitis. Gastroenterology 1997; 112: 991-9.
26. Jafri SF, Marshall JB. Ascites associated with antibiotic-associated pseudomembranous colitis. South Med J 1996; 89: 1014-7.
27. Rubin MS, Bodenstein, LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350-4.
28. Tedesco FJ, Barton RW, Alpers DH. Clindamycin associated colitis. A prospective study. Ann Intern Med 1974; 81: 429-33.
29. Drapkin MS, Worthington MG, Chang TW, Razvi SA. Clostridium difficile colitis mimicking acute peritonitis. Arch Surg 1985; 120: 1321-2.
30. Yankes JR, Baker ME, Cooper C, Garbutt JCT. Appearance of focal pseudomembranous colitis. J Comput Assist Tomogr 1988; 12: 394-6.
31. Bartlett JG. Clostridium difficile: clinical considerations. Rev Infect Dis 1990; 12: S243-51.
32. Vaishnavi C, Kochhar R, Bhasin, DK, Thennarasu K, Singh K. Simultaneous assay for Clostridium difficile and fecal lactoferrin in ulcerative colitis. Trop Gastroenterol 2003; 24: 13-6.
33. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554 80.
34. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
35. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-8.
36. Mahajan LA, Hupertz V, Mahajan, S, Lisa F, John D. The appendix: A possible reservoir for Clostridium difficile. Am J Gastroenterol 2006; 101: S392.
37. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
38. Pantosti A, Cerquetti M, Gianfrilli PM. Electrophoretic characterization of Clostridium difficile strains isolated from antibiotic-associated colitis and other conditions. J Clin Micobiol 1988; 26: 540-3.
39. McFarland LV, Elmer GW, Stamm WE, Mulligan ME. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun 1991; 59: 2456-62.
40. Cheng SH, Lu JJ, Young TG, Perng CL, Chi WM. Clostridium difficile-associated disease: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production and genotyping results. Clin Infect Dis 1997; 25: 157-8.
41. Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2001; 80: 88-101.
42. Testore GP, Nardi F, Babudieri S, Giuliano M, Di Rosa R, Panichi G. Isolation of Clostridium difficile from jejunum: identification of a reservoir for disease? J Clin Pathol 1986; 39: 861-2.
43. Boland E, Thompson JS. Fulminant Clostridium difficile enteritis after proctocolectomy and ileal pouch-anal anastomosis. Gastroenterol Res Pract 2009; 2008: 1-5.
44. Navaneethan U, Giannella RA. Thinking beyond the colon-small bowel Involvement in Clostridium difficile infection. Gut Pathog 2009; 19: 7.
45. Daruwala C, Mercogliano G, Newman G, Ingerman MJ. Bacteremia due to Clostridium difficile: Case report and review of the literature. Clin Med Case Reports 2009; 2: 5-9.
46. Libby DB, Bearman G. Bacteremia due to Clostridium difficile - review of the literature. Int J Infect Dis 2009; 13: e305-9.
47. Birnbaum J, Bartlett JG, Gelber AC. Clostridium difficile: an under recognized cause of reactive arthritis? Clin Rheumatol 2008; 27: 253-5.
48. Ducroix-Roubertou S, Genet C, Rogez JP, Weinbreck P, Denes E. Reactive arthritis due to Clostridium difficile. Med Mal Infect 2005; 35: 419-21.
49. Vaishnavi C. Established and potential risk factors for Clostridium difficile infection. Indian J Med Microbiol 2009; 27: 291-302.
50. Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol 2007; 51: 1209-14.
51. Johnson S, Gerding DN. Clostridium difficile associated diarrhoea. Clin Infect Dis 1998; 26: 1027-36.
52. West, M., Pirenne, J., Chavers, B Gillingham, K, Sutherland, DE, Dunn, DL, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999; 13: 318-23.
53. Keven K, Basu A, Re L. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004; 6: 10-14.
54. Bartlett JG. Clinical practice: Antibiotic associated diarrhoea. N Engl J Med 2002; 346: 334-9.
55. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Clostridium difficile: an under appreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-72.
56. Manian FA, Meyer L. CDAD rates. Infect Control Hosp Epidemiol 1995; 16: 63-5.
57. Sharma AK, Holder FE. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation. Clin Infect Dis 1998; 27: 1540-1.
58. Sohi S, Cohen RD. Management of refractory ulcerative colitis. Curr Treat Options Gastroenterol 2006; 9: 234-45.
59. Arnold C, von Sanden S, Theilacker C, Blum HE. Ulcerous colitis and infection with cytomegalovirus, herpes simplex virus and Clostridium difficile. Zeitschriff fur Gastroenterologie 2008; 46: 780-3.
60. Milligan DW, Kelley JK. Pseudomembranous colitis in a leukemia unit: a report of five fatal cases. J Clinical Pathol 1979; 32: 1237-43.
61. Chen FC, Woods R. Pseudomembranous panenteritis and septicaemia in a patient with ulcerative colitis. Aust N Z J Surg 1996; 66: 565-7.
62. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol 2001; 15: 511-21.
63. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243-5.
64. Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 2007; 37: 241-7.
65. Nachnani JS, Bulchandani D, Allen MJ. Proton pump inhibitors are an independent risk factor for an increased length of hospital stay in patients with Clostridium difficile infection. Indian J Gastroenterol 2008; 27: 171-2.
66. Emoto M, Kawarabayashi T, Hachisuga T, Eguchi F, Shirakawa K. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol 1996; 61: 369-72.
67. Resnik E, Lefevre CA. Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Internat J Gynecol Cancer 2001; 9: 512-4.
68. Kumar B, Vaishnavi C, Sandhu K, Kaur I. Clostridium difficile toxin assay in psoriatic patients. Trop Gastroenterol 2004; 25: 164-7.
69. Gellad ZF, Alexander BD, Liu JK, Griffith BC, Meyer AM, Johnson JL, et al. Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients. Transpl Infect Dis 2007; 17: 1-5.
70. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 2007; 8: 557-66.
71. Loo VG, Poirier L, Miller MA, Oughton M, Libman M, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
72. Weiss B, Kleinkauf N, Neumann M, Eckmanns T, Michels H, Jansen A. Risk factors for Clostridium difficile ribotype 027 infection in Germany: preliminary results of a retrospective case-control study. 18th European Congress of Clin. Microbial & Infectious Diseases, Barcelona, Spain Abst 2008. p. 1480.
73. Tabaqchali S, Jumma P. Diagnosis and management of Clostridium difficile infection. BMJ 1995; 310: 1375-80.
74. Borriello SP, Barclay FE. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol 1984; 19: 339-50.
75. Rupnik M, Kato N, Grabnar M, Kato H. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol 2003; 41: 1118-25.
76. Krivan HC, Clark GF, Smith DF, Wilkins TD. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3 Gal beta 1-4GlcNAc. Infect Immun 1986; 53: 573-81.
77. Calabi E, Calabi F, Phillips AD. Fairweather NF. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun 2002; 70: 5770-8.
78. Pechine S, Gleizes A, Janoir C, Gorges-Kergot R, Bare M-C, Delmee M, et al. Immunological properties of surface proteins of Clostridium difficile. J Med Microbiol 2005; 54: 193-6.
79. Janoir C, Pechine S, Grosdidier C, Collignon A. Cwp 84, a surface associated protein of Clostridium difficile is a cysteine protease with degrading activity on extracellular matrix proteins. J Bacteriol 2007; 159: 7174-80.
80. Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhea. Eur J Gastroenterol Hepatol 1996; 8: 1041-7.
81. Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs, SL. Comparison of toxiotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiol 2001; 147: 439-47.
82. Stubbs SL, Rupnik M, Gilbert M, Brazier JS, Duerden BI, Popoff MR. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol L ett 2000; 186: 307-12.
83. Just I, Selzr J, Wilm M, von Eichel-Streiber C, Mann M, Akatories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 1995; 375: 500-3.
84. Just I, Wilm M, Selzr J, Rex G, von Eichel-Streiber C, Mann M, et al. The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 1995; 270: 13932-6.
85. Linevsky JK, Pothoulakis C, Keates S, Warny M, Keates, AC, LaMont JT, et al. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol Gastrointest L iver Physiol 1997; 273: G1333-40.
86. Lima AA, Lyerly DM, Wilkins TD, Innes DJ, Guerrant RL. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun 1988; 56: 582-8.
87. Triadafilopoulos G, Pothoulakis C, Weiss R, Giampaolo C, LaMont JT. Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Role of prostaglandins and leukotrienes. Gastroenterology 1987; 92: 1174-80.
88. Katyal R, Vaishnavi C, Singh K. Faecal excretion of brush border membrane enzymes in patients with Clostridium difficile diarrhea. Indian J Med Microbiol 2002; 20: 178-82.
89. Hecht G, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 1988; 82: 1516-24.
90. Castagliuolo I, Keats AC, Wang CC, Pasha A, Valenick L, Pothoulakis C, et al. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998; 275: G68-75.
91. Pothoulakis C, LaMont JT. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest L L iver Physiol 2001; 280: G178-83.
92. Brito GA, Fujji J, Carneiro-Filho BA, Lima AA, Obrig T, Guerrant RL. Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J Infect Dis 2002; 186: 1438-47.
93. Altaie SS, Meyer P, Dryja D. Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J Clin Microbiol 1994; 32: 51-3.
94. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. Effect of Clostridium difficile toxins given intragastrically to animals. Infect Immun 1985; 35: 1147-50.
95. Fiorentini C, Thelestam M. Clostridium difficile toxin A and its effects on cells. Toxicon 1991; 29: 543-67.
96. Siffert JC, Baldacini O, Kuhry JG, Wachsmann D, Benabdelmoumene S, Faradji A, et al. Effects of Clostridium difficile toxin B on human monocytes and macrophages: possible relationship with cytoskeletal rearrangement. Infect Immun 1993; 61: 1082-90.
97. Just I, Fritz G, Giry M, Popoff MR, Boquet P, Hegenbarth S, et al. Clostridium difficile toxin B acts on the GTP-binding protein Rho. J Biol Chem 1994; 269: 10706-12.
98. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin B disrupts barrier function of T84 monolayers. Gastroenterology 1992; 102: 416-23.
99. Popoff MR, Rubin EJ, Gill DM, Boquet P. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 1988; 56: 2299-306.
100. Rupnik M. How to detect Clostridium difficile variant strains in a routine laboratory. Clin Microb Infect Dis 2001; 7: 417-20.
101. Geric B, Johnson S, Gerding DN, Grabnar M, Rupnik M. 101. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol 2003; 41: 5227-32.
102. Bartlett JG, Cang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med 1978; 298: 531-4.
103. Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol 2003; 41: 531-4.
104. Kato H, Yokoyama T, Kato H, Arakawa Y. Rapid and simple method for detecting the toxin B gene of Clostridum difficile in stool specimens by loop mediated isothermal amplification. J Clin Microbiol 2005; 43: 6108-12.
105. Teasley PG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet 1983; 2: 1043-6.
106. Delmee M, Buts J-P. Clostridium difficile-associated diarrhoea in children. In: Buts JP, Sokal EM, editors. Management of digestive and liver disorders in infants and children. Elsevier Science Publishers; 1993. p. 371-9.
107. Barbut F, Petit J-C. Epidemiology of Clostridium difficile associated infections. Clin Microbiol Infect 2001; 7: 405-10.
108. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005; CD004610.
109. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis; case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580-5.
110. Dutta P, Niyogi SK, Mitra U, Rasardy R, Bhattacharya MK, Chakraborty S. Clostridium difficile in antibiotic associated pediatric diarrhea. Indian Pediatr 1994; 31: 121-6.
111. Dhawan B, Chaudhry R, Sharma N. Incidence of Clostridium difficile infection: a prospective study in an Indian hospital. J Hosp Infect 1999; 43: 275-80.
112. Vaishnavi C, Kochhar R, Bhasin DK, Thapa BR, Singh K. Detection of Clostridium difficile toxin by an indigenously developed latex agglutination assay. Trop Gastroenterol 1999; 20: 33-5.
113. Vaishnavi C, Bhasin DK, Singh K. Faecal lactoferrin assay as a cost effective tool for intestinal inflammation. Am J Gastroenterol 2000; 95: 3002.
114. Vaishnavi C, Thapa BR, Thennarasu K, Singh K. Faecal lactoferrin assay as an adjunct to Clostridium difficile diarrhea. Indian J Pathol Microbiol 2002; 45: 69-74.
115. Gupta U, Jadav RN. Clostridium difficile in hospital patients. Indian J Med Res 1985; 82: 398-401.
116. Niyogi SK, Dutta P, Dutta D, Mitra U, Sikdar S. Clostridium difficile and its cytotoxin in hospitalized children with acute diarrhea. Indian Paediatrics 1991; 28: 1129-32.
117. Niyogi SK, Bhattacharya SK, Dutta P, Naik TN, De SP, Sen D, et al. Prevalence of Clostridium difficile in hospitalised patients with acute diarrhoea in Calcutta. J Diarrhoeal Dis Res 1991; 9: 16-9.
118. Bhattacharya MK, Niyogi SK, Rasaily R, Bhattacharya SK, Dutta P, Nag A, et al. Clinical manifestation of Clostridium difficile enteritis in Calcutta. J Assoc Physicians India 1991; 39: 683-4.
119. Niyogi SK. Antimicrobial susceptibility of Clostridium difficile strains isolated from hospitalised patients with acute diarrhoea. J Diarrhoeal Dis Res 1992; 10: 156-8.
120. Kochhar R, Ayyagari A, Goenka MK, Dhali GK, Aggarwal R, Mehta SK. Role of infectious agents in exacerbation of ulcerative colitis in India: A study of Clostridium difficile. J Clin Gastroenterol 1993; 16: 26-30.
121. Vaishnavi C, Bhasin DK, Kochhar R, Singh K. Clostridium difficile toxin and faecal lactoferrin assays in adult patients. Microbes Infect 2000; 2: 1827-30.
122. Kang G, Srivastava A, Pulimood AB, Dennison D, Chandy M. Etiology of diarrhea in patients undergoing allogeneic bone marrow transplantation in South India. Transplantation 2002; 73: 1247-51.
123. Gogate A, De A, Nanivadekar R, Mathur M, Saraswathi K, Jog A, et al. Diagnostic role of stool culture and toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children. Indian J Med Res 2005; 122: 518-24.
124. Vaishnavi C, Kaur S, Singh K. Clostridium perfringens type A and antibiotic associated diarrhoea. Indian J Med Res 2005; 122: 52-6.
125. Balamurugan R, Balaji V, Ramakrishna BS. Estimation of faecal carriage of Clostridium difficile in patients with ulcerative colitis using real time polymerase chain reaction. Indian J Med Res 2008; 127: 472-7.
126. Chaudhry R, Joshy L, Kumar L, Dhawan B. Changing pattern of Clostridium difficile associated diarrhoea in a tertiary care hospital: a 5 year retrospective study. Indian J Med Res 2008; 127: 377-82.